Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is one of the best drug stocks to buy right now. On September 5, RBC Capital raised the firm’s price target on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to $149 from$144 while keeping an Outperform rating on the shares. Neurocrine Biosciences, Inc. (NBIX): Among Small-Cap Healthcare Stocks Hedge Funds is Buying The firm told investors in a research note that, according to its latest analysis of prescription trends, Crenessity’s strong launch is expected to con ...